RxDoctor Payments Data

Tarrant McCarley

Family · Wartburg, TNNPI 1164766937

Payments from drug & device makers

$1,483in general payments, 2019–2025

Across 87 payments — averaging $17.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$282
  • GSK$210
  • Novo Nordisk$204
  • Neurocrine Biosciences, Inc.$147
  • Teva Pharmaceuticals USA, Inc.$125
  • AstraZeneca$85
  • plus $431 from 15 others

What the payments were for

  • Food & beverage$1,483100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,483 in reported general payments places this provider in the 70th percentile of 6,706 family providers in Tennessee.

See all family providers in Tennessee

Medicare billing

Part B allowed, 2024
$1,825
Medicare patients
28
Services billed
120

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Tresiba Flextouch U-200Insulin Degludec37$61,387
Trelegy ElliptaFluticasone/Umeclidin/Vilanter49$60,512
OzempicSemaglutide25$35,077
EliquisApixaban20$27,071
MounjaroTirzepatide22$26,139
TrulicityDulaglutide13$14,666
Bevespi AerosphereGlycopyrrolate/Formoterol Fum19$11,164
Breztri AerosphereBudesonide/Glycopyr/Formoterol12$10,711
InvokanaCanagliflozin12$7,453
LinzessLinaclotide13$6,918
Lantus SolostarInsulin Glargine,hum.Rec.Anlog20$4,747
Dexlansoprazole DrDexlansoprazole15$3,575
Albuterol Sulfate HfaAlbuterol Sulfate103$3,350
LantusInsulin Glargine,hum.Rec.Anlog11$3,285
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen104$3,197

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta$210$60,51249 claims
Lilly USA, LLCMounjaro, Trulicity$18$40,80435 claims
Novo NordiskOzempic$204$35,07725 claims
AstraZenecaBevespi Aerosphere, Breztri Aerosphere$85$21,87531 claims
Johnson & JohnsonInvokana$12$7,45312 claims
AbbVieLinzess$282$6,91813 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 6,706 family providers in Tennessee.

Other family in Wartburg

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →